Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 1 778.6 INR -1.05%
Market Cap: 90.2B INR
Have any thoughts about
Orchid Pharma Ltd?
Write Note

Orchid Pharma Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orchid Pharma Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Orchid Pharma Ltd
NSE:ORCHPHARMA
Other Long-Term Assets
â‚ą91.3m
CAGR 3-Years
21%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Long-Term Assets
â‚ą18.6B
CAGR 3-Years
24%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Long-Term Assets
â‚ą8.3B
CAGR 3-Years
-8%
CAGR 5-Years
2%
CAGR 10-Years
19%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Long-Term Assets
â‚ą46.8B
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
13%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Long-Term Assets
â‚ą6.1B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
15%
M
Mankind Pharma Ltd
NSE:MANKIND
Other Long-Term Assets
â‚ą1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orchid Pharma Ltd
Glance View

Market Cap
90.2B INR
Industry
Pharmaceuticals

Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

ORCHPHARMA Intrinsic Value
1 261.31 INR
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Orchid Pharma Ltd's Other Long-Term Assets?
Other Long-Term Assets
91.3m INR

Based on the financial report for Mar 31, 2024, Orchid Pharma Ltd's Other Long-Term Assets amounts to 91.3m INR.

What is Orchid Pharma Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-59%

Over the last year, the Other Long-Term Assets growth was 352%. The average annual Other Long-Term Assets growth rates for Orchid Pharma Ltd have been 21% over the past three years , -59% over the past five years .

Back to Top